TrialJournal of Crohn's & colitis2025

Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies.

Remo Panaccione et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.